CBIO
Crescent Biopharma, Inc.
Biotechnology
Market Cap$506M
5Y Perf.-95.2%
Build Your Comparison
Side-by-side financial analysisCBIO
RCUS
IMVT
Try popular comparisons:
Stock Comparison
CBIO vs RCUS vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.35B
5Y Perf.+2.4%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$6.75B
5Y Perf.+36.8%
CBIO vs RCUS vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  CBIO |  RCUS |  IMVT |
|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $506M | $2.35B | $6.75B |
| Revenue (TTM) | $12M | $236M | $0.00 |
| Net Income (TTM) | $-162M | $-369M | $-506M |
| Gross Margin | 100.0% | 90.7% | — |
| Operating Margin | -13.7% | -168.6% | — |
| Total Debt | $2M | $99M | $72K |
| Cash & Equiv. | $213M | $222M | $902M |
CBIO vs RCUS vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CBIO
RCUS
IMVT
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Crescent Biopharma,… (CBIO) | 100 | 4.8 | -95.2% |
| Arcus Biosciences, … (RCUS) | 100 | 102.4 | +2.4% |
| Immunovant, Inc. (IMVT) | 100 | 136.8 | +36.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CBIO vs RCUS vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CBIO and RCUS are tied at the top with 2 categories each — the right choice depends on your priorities. Arcus Biosciences, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
CBIO
Crescent Biopharma, Inc.
The Income Pick
CBIO has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.
- beta 0.82
- Lower volatility, beta 0.82, Low D/E 0.8%, current ratio 6.56x
- Beta 0.82, current ratio 6.56x
Best for: income & stability and sleep-well-at-night
RCUS
Arcus Biosciences, Inc.
The Growth Play
RCUS is the clearest fit if your priority is growth exposure.
- Rev growth -4.3%, EPS growth -4.8%, 3Y rev CAGR 30.2%
- +156.6% vs CBIO's +10.5%
- -35.3% ROA vs CBIO's -88.2%
Best for: growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 230.5% 10Y total return vs RCUS's 37.1%
- 2.6% margin vs CBIO's -13.6%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  CBIO | 365.3% revenue growth vs IMVT's -22.2% |
| Quality / Margins |  IMVT | 2.6% margin vs CBIO's -13.6% |
| Stability / Safety | CBIO | Beta 0.82 vs RCUS's 1.98, lower leverage |
| Dividends | Tie | None of these 3 stocks pay a meaningful dividend |
| Momentum (1Y) |  RCUS | +156.6% vs CBIO's +10.5% |
| Efficiency (ROA) | RCUS | -35.3% ROA vs CBIO's -88.2% |
CBIO vs RCUS vs IMVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
Segment breakdown not available.
CBIO vs RCUS vs IMVT — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMVTLAGGINGCBIO
Who Leads Where
IMVT leads in 2 of 6 categories
RCUS leads 1 • CBIO leads 0 • 2 tied
Explore the data ↓CBIOCrescent Biopharma, I…
0leads
RCUSArcus Biosciences, In…
1leads
IMVTImmunovant, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs RCUSvs CBIOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RCUS4/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMVT4/8
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RCUS leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
RCUS and IMVT operate at a comparable scale, with $236M and $0 in trailing revenue. Profitability is closely matched — net margins range from -156.4% (RCUS) to -13.6% (CBIO).
| Metric | CBIOCrescent Biopharm… | RCUSArcus Biosciences… | IMVTImmunovant, Inc. |
|---|---|---|---|
| RevenueTrailing 12 months | $12M | $236M | $0 |
| EBITDAEarnings before interest/tax | -$163M | -$391M | -$532M |
| Net IncomeAfter-tax profit | -$162M | -$369M | -$506M |
| Free Cash FlowCash after capex | -$27M | -$489M | -$407M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +90.7% | — |
| Operating MarginEBIT ÷ Revenue | -13.7% | -168.6% | — |
| Net MarginNet income ÷ Revenue | -13.6% | -156.4% | — |
| FCF MarginFCF ÷ Revenue | -2.3% | -2.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -39.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +10.3% | +10.5% | -14.1% |
RCUS leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
Evenly matched — CBIO and RCUS and IMVT each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | CBIOCrescent Biopharm… | RCUSArcus Biosciences… | IMVTImmunovant, Inc. |
|---|---|---|---|
| Market CapShares × price | $506M | $2.3B | $6.8B |
| Enterprise ValueMkt cap + debt − cash | $294M | $2.2B | $5.8B |
| Trailing P/EPrice ÷ TTM EPS | -1.43x | -7.08x | -11.87x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 46.63x | 9.50x | — |
| Price / BookPrice ÷ Book value/share | 0.94x | 3.97x | 7.04x |
| Price / FCFMarket cap ÷ FCF | — | — | — |
Evenly matched — CBIO and RCUS and IMVT each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
IMVT leads this category, winning 4 of 8 comparable metrics.
Profitability & Efficiency
IMVT delivers a -68.2% return on equity — every $100 of shareholder capital generates $-68 in annual profit, vs $-101 for CBIO. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCUS's 0.16x. On the Piotroski fundamental quality scale (0–9), CBIO scores 7/9 vs RCUS's 0/9, reflecting strong financial health.
| Metric | CBIOCrescent Biopharm… | RCUSArcus Biosciences… | IMVTImmunovant, Inc. |
|---|---|---|---|
| ROE (TTM)Return on equity | -100.9% | -69.0% | -68.2% |
| ROA (TTM)Return on assets | -88.2% | -35.3% | -62.2% |
| ROICReturn on invested capital | — | -64.1% | — |
| ROCEReturn on capital employed | -132.6% | -42.1% | -68.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 0 | 2 |
| Debt / EquityFinancial leverage | 0.01x | 0.16x | 0.00x |
| Net DebtTotal debt minus cash | -$212M | -$123M | -$902M |
| Cash & Equiv.Liquid assets | $213M | $222M | $902M |
| Total DebtShort + long-term debt | $2M | $99M | $72,000 |
| Interest CoverageEBIT ÷ Interest expense | -148.19x | -13.38x | — |
IMVT leads this category, winning 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $30,700 today (with dividends reinvested), compared to $667 for CBIO. Over the past 12 months, RCUS leads with a +156.6% total return vs CBIO's +10.5%. The 3-year compound annual growth rate (CAGR) favors IMVT at 14.9% vs CBIO's -53.6% — a key indicator of consistent wealth creation.
| Metric | CBIOCrescent Biopharm… | RCUSArcus Biosciences… | IMVTImmunovant, Inc. |
|---|---|---|---|
| YTD ReturnYear-to-date | +65.5% | +0.0% | +26.9% |
| 1-Year ReturnPast 12 months | +10.5% | +156.6% | +103.6% |
| 3-Year ReturnCumulative with dividends | -90.0% | +15.9% | +51.6% |
| 5-Year ReturnCumulative with dividends | -93.3% | -6.4% | +207.0% |
| 10-Year ReturnCumulative with dividends | -97.7% | +37.1% | +230.5% |
| CAGR (3Y)Annualised 3-year return | -53.6% | +5.0% | +14.9% |
IMVT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CBIO and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
CBIO is the less volatile stock with a 0.82 beta — it tends to amplify market swings less than RCUS's 1.98 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.6% from its 52-week high vs CBIO's 66.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CBIOCrescent Biopharm… | RCUSArcus Biosciences… | IMVTImmunovant, Inc. |
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.82x | 1.98x | 1.67x |
| 52-Week HighHighest price in past year | $27.41 | $28.72 | $36.27 |
| 52-Week LowLowest price in past year | $8.72 | $7.91 | $14.32 |
| % of 52W HighCurrent price vs 52-week peak | +66.9% | +81.1% | +90.6% |
| RSI (14)Momentum oscillator 0–100 | 43.6 | 39.3 | 51.9 |
| Avg Volume (50D)Average daily shares traded | 270K | 1.1M | 1.9M |
Evenly matched — CBIO and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CBIO as "Buy", RCUS as "Buy", IMVT as "Buy". Consensus price targets imply 79.9% upside for CBIO (target: $33) vs 32.8% for IMVT (target: $44).
| Metric | CBIOCrescent Biopharm… | RCUSArcus Biosciences… | IMVTImmunovant, Inc. |
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $33.00 | $31.17 | $43.67 |
| # AnalystsCovering analysts | 13 | 18 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMVT leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). RCUS leads in 1 (Income & Cash Flow). 2 tied.
Best OverallImmunovant, Inc. (IMVT)Leads 2 of 6 categories
Loading custom metrics...
CBIO vs RCUS vs IMVT: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is CBIO or RCUS or IMVT a better buy right now?
Analysts rate Crescent Biopharma, Inc.
(CBIO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CBIO or RCUS or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +207. 0%, compared to -93. 3% for Crescent Biopharma, Inc. (CBIO). Over 10 years, the gap is even starker: IMVT returned +230. 5% versus CBIO's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CBIO or RCUS or IMVT?
By beta (market sensitivity over 5 years), Crescent Biopharma, Inc.
(CBIO) is the lower-risk stock at 0. 82β versus Arcus Biosciences, Inc. 's 1. 98β — meaning RCUS is approximately 142% more volatile than CBIO relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CBIO or RCUS or IMVT?
On earnings-per-share growth, the picture is similar: Immunovant, Inc.
grew EPS -1. 5% year-over-year, compared to -815. 0% for Crescent Biopharma, Inc.. Over a 3-year CAGR, CBIO leads at 424. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CBIO or RCUS or IMVT?
Immunovant, Inc.
(IMVT) is the more profitable company, earning 0. 0% net margin versus -1419. 6% for Crescent Biopharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -1407. 5% for CBIO. At the gross margin level — before operating expenses — CBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CBIO or RCUS or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CBIO or RCUS or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Crescent Biopharma, Inc.
(CBIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 82)). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CBIO: -97. 7%, RCUS: +37. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CBIO and RCUS and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.